The third CDK4/6 inhibitor that received FDA approval in metastatic breast cancer was abemaciclib and is currently under investigation as an adjuvant treatment in patients with high-risk node-positive early breast cancer in MonarchE trial [9]. The gene discussed is CDK4; the disease is breast carcinoma.